CCL2 and diabetes mellitus: In vivo administration of A-285222 completely blocked diabetes-induced NFAT-transcriptional activity in the aorta, leading to reduced expression of IL-6, OPN, MCP-1, ICAM-1, CD68 and TF, all established players in atherogenesis, as well as to reduced diabetes-induced atherosclerosis.